SCHEMBL3369356

SCHEMBL3369356

CCOC(=O)C(CCC1CCCCC1)N[C@@H](CCCCNC(=O)C(F)(F)F)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
METAP2 P50579 1/20 0.39
EPHX1 P07099 1/20 0.38
REN P00797 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CPB2 Q96IY4 4/20 0.35
BCHE P06276 2/20 0.34
CA12 O43570 1/20 0.34
CA2 P00918 1/20 0.34
CA3 P07451 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA5A P35218 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15101628 0.80 MME (0.45) SMN1; SMN2POLB
SCHEMBL901541 0.80 MME (0.45) SMN1; SMN2POLB
SCHEMBL901542 0.80 MME (0.45) SMN1; SMN2POLB
SCHEMBL5351447 0.77 METAP2 (0.42) TSHRSMN1; SMN2METAP2EPHX1REN
SCHEMBL3369358 0.77 METAP2 (0.42) TSHRSMN1; SMN2METAP2EPHX1REN
SCHEMBL5346764 0.77 SMN1; SMN2 (0.46) SMN1; SMN2POLBMEN1KMT2A
SCHEMBL4668351 0.75 METAP2 (0.53) SMN1; SMN2METAP2RENMEN1KMT2A
SCHEMBL3372489 0.75 METAP2 (0.53) SMN1; SMN2METAP2RENMEN1KMT2A
SCHEMBL11529874 0.75 POLB (0.51) TSHRSMN1; SMN2EPHX1ALDH1A1POLB
SCHEMBL11533133 0.75 POLB (0.51) TSHRSMN1; SMN2EPHX1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253299-B2 Process for purifying n2-(1(s)-ethoxycarbonyl-3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2007-08-07 US claimed
US-20040147773-A1 Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2004-07-29 US claimed
EP-1405845-A1 METHOD FOR PURIFYING N2-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-N6-TRIFLUOROACETYL-L-LYSINE KANEKA CORPORATION (JP) 2004-04-07 EP claimed
EP-1679303-B1 Process for preparing 1-alkoxycarbonyl-3-phenylpropyl derivative KANEKA CORP (JP) 2010-09-15 EP disclosed
US-7253299-B2 Process for purifying n2-(1(s)-ethoxycarbonyl-3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2007-08-07 US disclosed
EP-1679303-A1 Process for preparing 1-alkoxycarbonyl-3-phenylpropyl derivative Kaneka Corporation (JP) 2006-07-12 EP disclosed
EP-0903337-B1 PROCESS FOR THE PREPARATION OF 1-ALKOXYCARBONYL-3-PHENYLPROPYL DERIVATIVES KANEKA CORP (JP) 2006-04-12 EP disclosed
US-20040147773-A1 Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KANEKA CORPORATION (JP) 2004-07-29 US disclosed
EP-1405845-A1 METHOD FOR PURIFYING N2-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-N6-TRIFLUOROACETYL-L-LYSINE KANEKA CORPORATION (JP) 2004-04-07 EP disclosed
EP-0903337-A1 PROCESS FOR THE PREPARATION OF 1-ALKOXYCARBONYL-3-PHENYLPROPYL DERIVATIVES KANEKA CORPORATION (JP) 1999-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147773-A1 Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine KARS1, L3MBTL1, PKN2 TSHR 3787/4885SMN1; SMN2 1082/4885METAP2 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.